About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

354,475 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/02/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/02/2020.
Our Science

Oral HMA (CC-486)

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Proposed Mechanism of Action

The epigenetic modifier CC-486 (an oral formulation of azacitidine)1 is a cytidine nucleoside analogue that is incorporated into newly synthesized DNA as well as RNA.2-4 Once incorporated, CC-486 may deplete DNA methyltransferase 1 (DNMT1), induce DNA damage, and promote hypomethylation of DNA.2,5 The antineoplastic effects of CC-486 are hypothesized to result from this DNA hypomethylation and the ultimate unsilencing of genes involved in cell cycle regulation.2,5

CC-486 Hypothesized Mechanism of Action

CC-486 is an epigenetic modifier hypothesized to induce malignant cell death through the inhibition of protein synthesis or the activation of DNA damage response pathways in hematologic malignancies.

Rationale for Investigation of CC-486 in Hematologic Malignancies

Oral HMA (CC-486) by Disease State

Oral HMA (CC-486) in Acute Myeloid Leukemia

Phase 3
Post-induction AML maintenance

View Trials Investigating Oral HMA (CC-486) in Acute Myeloid Leukemia
View Rationale for Clinical Development

Rationale for Clinical Development

Preclinical studies suggest that the antileukemic effects of CC-486 include direct cytotoxicity due to inhibition of protein synthesis and DNA damage and the re-expression of aberrantly silenced tumor suppressor genes due to DNA hypomethylation.2,5-7 In vitro studies have shown that serial cycles of DNA replication are required to induce hypomethylation, and extensive demethylation requires prolonged exposure.2,3,8 Extended dosing with CC-486 may prolong drug exposure, which is hypothesized to allow more opportunity for incorporation into cycling malignant cells.9

Most patients with acute myeloid leukemia (AML) will relapse following achievement of remission with intensive chemotherapy, and it has been shown that duration of remission is predictive of long-term outcomes.10,11 Stem cell transplant is associated with the lowest rates of relapse.11 However, not all patients are candidates for stem cell transplant, and relapse remains a significant problem even for patients who do receive a transplant.12,13 There is an unmet need to prolong duration of remission following intensive chemotherapy with or without stem cell transplant.

Oral HMA (CC-486) in Lymphoma

Phase 3
Angioimmunoblastic T-cell lymphoma

View Trials Investigating Oral HMA (CC-486) in Lymphoma
View Rationale for Clinical Development

Rationale for Clinical Development

Preclinical studies suggest that CC-486 has antitumor effects that include direct cytotoxicity due to activation of DNA damage response pathways, inhibition of protein synthesis, and re-expression of aberrantly silenced tumor suppressor genes due to DNA hypomethylation.2,5-7 One study in lymphoma cell lines has suggested that this hypomethylation may lead to re-expression of antitumor genes that are commonly silenced in non-Hodgkin lymphoma.14

Oral HMA (CC-486) in Myelodysplastic Syndromes

Phase 3
Lower-risk

Phase 2
Post hypomethylating agent (HMA) failure

View Trials Investigating Oral HMA (CC-486) in Myelodysplastic Syndromes
View Rationale for Clinical Development

Rationale for Clinical Development

Similar to the effects described in AML, CC-486 has exhibited antileukemic effects in preclinical studies.2,5-7 Additionally, prolonged exposure to CC-486 may allow more opportunity for incorporation into cycling malignant cells.2,3,8

Approximately two-thirds of patients with myelodysplastic syndromes (MDS) present with lower-risk disease that is generally viewed as having a favorable prognosis and is often treated with only supportive care.15,16 However, many patients with lower-risk disease have poor prognostic features and could benefit from early active treatment.15,17 The only potential cure for most patients with MDS remains stem cell transplant, which is generally reserved for younger patients with higher-risk disease.17 However, even patients who receive a transplant often relapse.17 There is an unmet need for additional treatment options in the post-transplant setting to improve disease-free survival.

View Related Pathways

References

  1. Garcia-Manero G, et al. Leukemia. 2008;22:1680-1684. PMID: 18548103
  2. Hollenbach PW, et al. PLoS One. 2010;5:e9001. PMID: 20126405
  3. Garcia-Manero G, et al. J Clin Oncol. 2011;29:2521-2527. PMID: 21576646
  4. Santi DV, et al. Proc Natl Acad Sci. 1984;91:6993-6997. PMID: 6209710
  5. Palii SS, et al. Mol Cell Biol. 2008;28:752-771. PMID: 17991895
  6. Herman JG, et al. Proc Natl Acad Sci. 1994;91:9700-9704. PMID: 7937876
  7. Li H, et al. Am J Obstet Gynecol. 2009;177.
  8. Lu LJ, Randerath K. Mol Pharmacol. 1984;26:594-603. PMID: 6208475
  9. Laille E, et al. PLoS One. 2015;10:e0135520. PMID: 26296092
  10. Estey E, et al. Blood. 1996;88:756. PMID: 8695828
  11. Pemmaraju N, et al. Am J Hematol. 2015;90:27-30. PMID: 25251041
  12. Bejanyan N, et al. Blood. 2013;122:2072.
  13. Rautenberg C, et al. Int J Mol Sci. 2019;20:E228. PMID: 30626126
  14. Wang W, et al. Int J Mol Med. 2015;36:698-704. PMID: 26133246
  15. Greenberg P, et al. Blood. 1997;89:2079-2088. PMID: 9058730
  16. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. V2.2019.
  17. Montalban-Bravo G and Garcia-Manero G. Am J Hematol. 2018;93:129. PMID: 29214694